Docoh
Loading...

BMRA Biomerica

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.

Company profile

Ticker
BMRA
Exchange
CEO
Zackary S. Irani
Employees
Incorporated
Location
Fiscal year end
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
IRS number
952645573

BMRA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 Apr 21
17 Apr 21
31 May 21
Quarter (USD)
Feb 21 Nov 20 Aug 20 May 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
May 20 May 19 May 18 May 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Biomerica earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.27M 5.27M 5.27M 5.27M 5.27M 5.27M
Cash burn (monthly) 137.07K (positive/no burn) 626.7K 458.68K 454.62K 644.89K
Cash used (since last report) 228.26K n/a 1.04M 763.81K 757.04K 1.07M
Cash remaining 5.04M n/a 4.23M 4.51M 4.52M 4.2M
Runway (months of cash) 36.8 n/a 6.7 9.8 9.9 6.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Dec 20 Zackary S. Irani NQSO Common Stock Grant Aquire A No No 6.36 78,616 500K 633,616
10 Dec 20 Steven Sloan NQSO Common Stock Grant Aquire A No No 6.36 25,000 159K 75,000
10 Dec 20 Barbieri Allen NQSO Common Stock Grant Aquire A No No 6.36 30,000 190.8K 220,000
10 Dec 20 Sirgo Mark A NQSO Common Stock Grant Aquire A No No 6.36 20,000 127.2K 145,000
10 Dec 20 Catherine Coste NQSO Common Stock Grant Aquire A No No 6.36 20,000 127.2K 45,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

39.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 31 26 +19.2%
Opened positions 8 7 +14.3%
Closed positions 3 7 -57.1%
Increased positions 11 8 +37.5%
Reduced positions 7 5 +40.0%
13F shares
Current Prev Q Change
Total value 29.8M 12.64M +135.8%
Total shares 4.58M 1.82M +151.2%
Total puts 55.1K 28K +96.8%
Total calls 0 22.4K EXIT
Total put/call ratio Infinity 1.3 +Infinity%
Largest owners
Shares Value Change
WELLINGTON TRUST Co N A 866K $4.31M NEW
Wellington Management 866K $4.31M +74.0%
Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio 723.2K $3.6M NEW
Vanguard 567.7K $2.83M -8.0%
Granahan Investment Management 510.92K $2.54M +469.4%
Russell Investments 393.4K $1.96M +307.2%
BLK Blackrock 210.03K $1.05M +1.5%
Millrace Asset 72.08K $359K NEW
Heritage Investors Management 69.35K $345K 0.0%
Geode Capital Management 64.28K $320K +16.1%
Largest transactions
Shares Bought/sold Change
WELLINGTON TRUST Co N A 866K +866K NEW
Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio 723.2K +723.2K NEW
Granahan Investment Management 510.92K +421.19K +469.4%
Wellington Management 866K +368.2K +74.0%
Russell Investments 393.4K +296.78K +307.2%
Millrace Asset 72.08K +72.08K NEW
Vanguard 567.7K -49.36K -8.0%
Renaissance Technologies 41.88K +41.88K NEW
WFC Wells Fargo & Co. 9.5K -16.23K -63.1%
BCS Barclays 24K -14.6K -37.8%

Financial report summary

?
Management Discussion
  • Our consolidated net sales were $6,692,711 for fiscal 2020 compared to $5,200,682 for fiscal 2019. This represents an increase of $1,492,029, or 28.7%. This increase in annual sales is primarily attributable to sales of COVID-19 tests during the last quarter of the fiscal year, which offset decreases in other product lines that were negatively impacted by the COVID-19 pandemic and related national and international mandates affecting consumers. Our consolidated net sales were $2,725,000 for the fiscal fourth quarter 2020, compared to $1,165,860 for fiscal fourth quarter of 2019.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: American, called, choose, compliance, Concurrently, default, downturn, EZ, failed, fell, hundred, internationally, launch, launched, longer, Moderna, moving, NASDAQ, ownership, percent, Pfizer, protein, readily, RNA, shifted, spike, typically, website
Removed: ASU, finger, higher, institution, prick, promising, similar, standard